FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
58.456,49 +3.278,06 (+5,94%)
Vir Biotechnology, Inc. (VIR)
Dopo ore:
| Chiusura precedente | 9,18 |
| Aperto | 10,14 |
| Denaro | 10,35 x 600 |
| Lettera | 10,45 x 200 |
| Min-Max giorno | 10,02 - 10,59 |
| Intervallo di 52 settimane | 7,61 - 27,48 |
| Volume | |
| Media Volume | 1.036.300 |
| Capitalizzazione | 1,411B |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,01 |
| Prossima data utili | 01 ago 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 32,29 |
GlobeNewswireVir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a virtual fireside Q&A at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25, at 7:00 a.m. PT / 10:00 a.m. ET. A live webcast of the fireside chat can be accessed under Events & Presentations in the Investors section of the
- GlobeNewswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include seven poster presentations, one of which is a late-breaking poster, and on
- GlobeNewswire
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on November 2, 2023. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section
